前列腺癌分子的异质性

Molecular heterogeneity of prostate cancer

前列腺癌在病理学、临床生物学及分子谱水平上表现出高度异质性。一些男性患有惰性前列腺癌,可以安全观察,而其他患者却罹患具有致命侵袭性的前列腺癌。在过去十年中,研究人员已开始揭示导致这些不同临床表型的基因组异质性,发现了不同的分子亚型,具有将前列腺癌从不了解且高度可变的异质性疾病转变为分子亚型集合的潜能。并且这些亚型的独特性已被用于预测临床结果,设计用于前列腺癌诊断的新型生物标志物,并开发新的治疗剂。本文就部分前列腺癌的分子亚型进行阐述,为将来研究前列腺癌的治疗方法提供线索。

Prostate cancer presents a high degree of heterogeneity in pathology,clinical biology and molecular spectrum.Some men suffer from indolent prostate cancer that can be followed safely,while others have aggressive,lethal prostate cancer.In the past decade,researchers have begun to unravel the genomic heterogeneity that contributes to these different clinical phenotypes.The emergence of different molecular subtypes has the potential to translate this disease from an unknown and highly variable heterogeneous disease into a collection of molecular subtypes.The uniqueness of these subclasses has been used to predict clinical outcomes,to design novel biomarkers for the diagnosis of prostate cancer and to develop new therapeutic agents.In this paper,we review some of the molecular subtypes of prostate cancer,with an aim to provide clues to future development of strategies for treating prostate cancer.